REVIEW

New Molecules Modulating Bone Metabolism – New Perspectives in the Treatment of Osteoporosis

I. ZOFKOVA¹, J. BLAHOS²

¹Institute of Endocrinology, Prague, Czech Republic, ²Osteocentrum, Central Military Hospital, Prague, Czech Republic

Received March 1, 2017
Accepted April 28, 2017

Summary
In this review the authors outline traditional antiresorptive pharmaceuticals, such as bisphosphonates, monoclonal antibodies against RANKL, SERMs, as well as a drug with an anabolic effect on the skeleton, parathormone. However, there is also a focus on non-traditional strategies used in therapy for osteolytic diseases. The newest antosteoporotic pharmaceuticals increase osteoblast differentiation via BMP signaling (harmine), or stimulate osteogenic differentiation of mesenchymal stem cells through Wnt/β-catenin (icarin, isoflavonoid cavunin, or sulfasalazine). A certain promise in the treatment of osteoporosis is shown by molecules targeting non-coding microRNAs (which are critical for osteoclastogenesis) or those stimulating osteoblast activity via epigenetic mechanisms. Vitamin D metabolites have specific antosteoporotic potencies, modulating the skeleton not only via mineralization, but markedly also through the direct effects on the bone microstructure.

Key words
RANKL • Sclerostin • Cathepsin K • Wnt/β-catenin • Estrogen • SERM • Bisphosphonates • Parathormone • Vitamin D • MicroRNA • Bone mineralization • Bone microarchitecture

Introduction
Osteoporosis is a serious public health problem. In the Czech Republic around 500,000 women and 200,000 men are affected by the disease. The osteoporotic population is endangered by increased morbidity and mortality due to fractures and their deteriorated healing, primarily in elderly, frail patients with a number of comorbidities and medicament therapies. Genetically determined both sensitivity and the side effects of therapy may complicate the choice of suitable long-term antosteoporotic treatment in individual patients. This article reviews traditionally used antosteoporotics and some recently discovered molecules with beneficial effects on the skeleton.

Under physiological conditions, bone is permanently remodeled to maintain its volume, microstructure and strength. When bone resorption predominates over formation, bone mass is endangered by progressive loss. The first choice of treatment in this case are usually bisphosphonates, drugs discovered 45 years ago. Bisphosphonates antagonize osteoclastogenesis through various mechanisms of action (Mac-Way et al. 2014, Nataka et al. 2015). Long-term oral or parenteral bisphosphonate therapy increases bone mineral density (BMD), bone volume, reduces bone porosity and markedly decreases fracture risk. A feature of this treatment is also its low cost. However, bisphosphonate therapy may be complicated by some serious side effects. Besides gastrointestinal intolerance, both oral and parenteral bisphosphonates may induce osteonecrosis of the jaw and/or atypical femoral fractures, partly explained by the inhibition of healing near bone cracks (Pazianas et al. 2016, Adler 2016). Furthermore, bisphosphonates are only marginally effective in patients with severe loss of bone mass, although effectivity of treatment may be improved by an advantageous pharmaceutical scheme, in
which bisphosphonate modified nanomaterials (conjugates with protein and polymers) directly target the bone and optimize drug delivery control (Ossipov 2015). The benefit/risk ratio in bisphosphonate therapy should be taken into account during the long-term process, which often requires more than one type of antiresorptive treatment.

Selective estrogen receptors modulators (SERMs) and their new analogs represent effective variant of antiresorptive therapy. With the exception of tamoxifen, raloxifene and lasofoxifene, a third generation molecule – bazedoxifene was synthesized. The latter drug significantly reduced the incidence of both vertebral and nonvertebral fractures in postmenopausal osteoporotic women. The pharmaceutical has been found safe in relation to endometrial and breast cancerogenesis (Komm and Chines 2012, An 2016).

Biological therapy has a good potential for increasing bone mass. The monoclonal antibody against RANKL, denosumab has positive effects on the microarchitectue of the skeleton (inhibition of erosion development and increase in cortical thickness and bone stiffness) (Bonani et al. 2016). Kamimura et al. (2017) showed inhibition of bone resorption and an increase in lumbar and hip BMD after one year of treatment with denosumab in patients unresponsive to bisphosphonate. Nevertheless, similar to bisphosphonates, a certain limitation of long-term denosumab treatment may be the reduced renewal of bone mass with subsequent osteonecrosis of the jaw and/or atypical femoral fractures (Qaisi et al. 2016).

Any inhibition of the cytokine network appears to slow down bone loss. Zerbini et al. (2017) analyzed clinical studies, in which patients with rheumatoid arthritis were treated with anti-TNF antibodies (such as infliximab, adalimumab, etanercept), or IL-1 and IL-6 antagonists (abatacept or rituximab). Although some patients in this study showed significant increase in BMD, others remained unaffected. Moreover, there was no consensus regarding their effects on fracture risk.

Bone formation is known to be stimulated via the Wnt/β-catenin pathway (Mosekilde et al. 2011). This pathway (expressed by osteocytes) is under the control of the SOST gene (located at chromosome region 17q12-q21) and inhibited by sclerostin. Mutations in SOST are known to be associated with low sclerostin level and increased bone mass. Undetectable sclerostin levels are manifested as autosomal-recessive sclerosteosis (Yavropoulou et al. 2014). On the other hand, bone diseases, such as osteoporosis, bone metastases and genetically dependent low bone mass, are often associated with sclerostin overproduction.

The inconvenience of antiresorption therapy could be eliminated by using exclusively anabolic pharmaceuticals, such as intact PTH (1-84) (preotact) or PTH (1-34) (teriparitide). At the present time, teriparitide is the only currently available bone anabolic molecule working via the inhibition of sclerostin and other metabolic circuits, such as DKK1 and/or frizzled protein. Small pulsatile doses of exogenous PTH increase BMD, improve microarchitecture and bone strength (Mosekilde et al. 2011), which results in lowering the fracture risk (reviewed by Tella and Gallagher 2014, Ishitaq et al. 2015). Cancellous bone density increased and trabecular separation decreased in postmenopausal women with osteoporosis treated with teriparitide irrespective of previous bisphosphonate administration (Fahrleitner-Pammer et al. 2016). There is no consensus on teriparitide treatment in osteoporotic diabetics. However, incretin derivatives, such as GLP-1 and GIP, appear to have good prospects in the prevention or treatment of osteoporosis in diabetics. After binding to osteoblastic receptors, there is an increase in bone formation (Nuche-Berenguer et al. 2009, Yamada 2012).

An alternative to exogenous PTH is the endogenous molecule, the secretion of which is stimulated through the inhibition of the calcium sensing receptor (CASR) (Widler 2011). A strong anabolic effect on the skeleton was also shown in PTH fragments, and PTHrP analog (abaloparatide), which are currently under investigation (Yamaguchi 2016).

Effectivity on fracture healing is strengthened when teriparitide is combined with other antosteoporotics. Casanova et al. (2016), using micro CT and quantitative histomorphometry showed that a three week administration of teriparitide together with zolendronic acid significantly increased bone volume and reduced trabecular spacing in mice with operatively induced fractures. Leder et al. (2016) in a randomized control trial described more significant increases in BMD at the hip and at the lumbar spine in postmenopausal women treated for two years with teriparitide and denosumab, when compared with women on single administration of these medicaments. Furthermore, better fracture repair could be obtained using a combination of teriparitide and anti-sclerostin and/or anti-cathepsin K antibodies (Tella and Gallagher 2014).
Further new molecules with antisclerostin effects

Subcutaneous administration of monoclonal antisclerostin antibodies, such as AbD09097, stimulates bone formation and increases bone mass through activation of the Wnt pathway, independently of bone remodeling (Boschert et al. 2016, Yavropoulou et al. 2014). Bone anabolic effects also have other antibodies against sclerostin, such as romosozumab or brosozumab. Both these drugs were successfully tested experimentally (reviewed by Tella and Gallagher 2014) and clinical trials in phase II are under way (Matsumoto 2015). Recently, the dose dependent stimulating effect of romosozumab on BMD at the spine was shown in 419 women with postmenopausal osteoporosis. The effect was markedly higher when compared with oral alendronate or the teriparatide (Larsson 2016). Similar effects of romosozumab on volumetric BMD at vertebral and total hip regions were observed in postmenopausal women by Genant et al. (2016). Additionally, a placebo controlled study on 7180 postmenopausal women showed, that romosozumab significantly decreased the risk of vertebral fractures after 12 months of treatment (Cosman et al. 2016).

Substances with anti-cathepsin effects

A recently discovered molecule with an antiosteoporotic effect is the monoclonal antibody against cathepsin K (CTSK) (Chan et al. 2016). Cathepsin K is a proteolytic enzyme, which degrades collagen I in the bone matrix and activates bone resorption. The cathepsin K antibody, due to the coupling between bone resorption and bone formation, inhibits both these processes, but more markedly bone resorption and only transiently bone formation. Long-term administration of cathepsin K antibodies, such as odanacatib, increased BMD and decreased the fracture rate (Boonen et al. 2012, Tella and Gallagher 2014). Some other cathepsin K inhibitors were evaluated, which are mostly in preclinical trials (Brömme et al. 2016).

Further non-traditional molecules with antiosteoporotic potential

Osteoclast formation is increased after the activation of T-cells through NF-κB, NFATc1 or c-Fos signaling. In bone tissue culture, this process was inhibited by β-carboline alkaloid harmine. Additionally, the alkaloid increased osteoblast differentiation via Runx2, osterix and bone morphogenetic peptide (BMP) (Yonezawa et al. 2011). Thus, harmine inhibits bone resorption and simultaneously activates bone formation. According to our knowledge, no study analyzing antiosteoporotic effectivity of the alkaloid in vivo has been published yet.

Certain antiosteoporotic activity was recorded in neoflavonoids, isolated chromatographically from Dalbergia sissoo heartwood. The flavonoids significantly stimulated calvarial osteoblast proliferation and mineralization (Kumar et al. 2014). Similarly, caviunin-based isoflavonoid stimulates bone formation via BMP2 and Wnt/β-catenin pathways, effectively inhibits osteoclastogenesis and repairs cortical bone. In ovarioectomized mice caviunin increased the mechanical strength of the vertebra and femur (Kushwaha et al. 2014). Similar anabolic effects on the skeleton mediated by Wnt/β-catenin signaling have been registered experimentally in aglycone of icaritin. Micro-CT analysis showed that icariine after 12-weeks of treatment increased BMD, trabecular bone number, trabecular thickness, reduced trabecular separation and increased biomechanical strength in oophorectomized rats (Chen et al. 2016). Some flavonoids could be positioned as potential pharmaceuticals or food supplements for fracture repair in postmenopausal osteoporosis.

Strong bioactivity in the culture of osteoblast-like cells has been shown in the three-dimensional calcium-bearing structure CaP1 (which has three molecules of water). In vivo, the substance increased bone mineralization without any toxicity (Shi et al. 2015). Bone regenerative effects were also found in synthetic diether molecules inhibiting RANKL-induced osteoclast formation (Doh et al. 2016), as well as in octacalcium phosphate, which increased bone mineralization via an irreversible transition into hydroxyapatite (Suzuki et al. 2008).

Furthermore, the food-derived compound sulforaphane and natural isothiocyanate promote osteoblast activity via epigenetic mechanisms. The molecule activates DNA demethylation increasing matrix mineralization. In mice it stimulates the expression of osteoblastic markers, such as Runx2, collagen 1A1 or ALP1, while inhibiting the nuclear factor-κB (RANKL) in osteocytes with subsequent increases in the trabecular number (Thaler et al. 2016). New strategies in therapy for osteolytic diseases consist of targeting non-coding
microRNAs (miRNAs), which control gene expression in osteoclasts. Thus, miRNAs appear to be the key molecules in the regulation of bone resorption (Li et al. 2016). Bone homoeostasis is determined by the osteogenesis/adipogenesis ratio in mesenchymal cells. Prevailing adipogenesis over osteogenesis is a principle pathological factor in accelerated bone loss. A strong modulator of osteogenic differentiation is the glutamate exchanger xCT (SLC7A11) sulfasalazine, which enhances the osteogeneic potential via an increase in BMP2/4 expression. Sulfasalazine administered in vivo inhibited bone loss in hypoestrogenic mice (Jin et al. 2016). Thus, sulfasalazine is a further candidate useful in the treatment of postmenopausal osteoporosis.

Potential bone protecting candidates are also growth factors, such as BMP, fibroblast growth factor (FGF) and vascular endothelial growth factor (VEGF) (Lee et al. 2015). Some of these mediate the action of other molecules (Jin et al. 2016). The beneficial effects of erythropoietin or statins on fracture healing are under investigation; however, sufficient evidence of their antiosteoporotic action in vivo is still lacking (Klontzas et al. 2016).

**New aspects of the bone protecting effects of vitamin D**

Vitamin D positively influences not only the mineralization of the bone matrix, but via genomic and non-genomic effects modulates the function of some non-skeletal systems, including muscles. D-hormone metabolites have been shown to influence bone homoeostasis directly. Bioactive 25(OH)D3, 1,25(OH)2D3, as well as 24R,25(OH)2D3 stimulated osteoblast growth and differentiation in vitro (van der Meijden et al. 2014). 1,25(OH)2D3 administered in vivo for 28 consecutive days, significantly increased bone formation, reduced bone resorption and increased trabecular bone volume in mice (Oelzner et al. 2014). Long-term treatment with 1α,25(OH)(2)-(3-hydroxypropyloxy)vitamin D₃ metabolite (eldecalcitol) suppressed bone turnover, decreased the risk of bone microstructure deterioration and increased bone biomechanical strength in ovariectomized rats (Takeda et al. 2015). Yamasaki et al. (2015) found that eldecalcitol increased bone formation at the endocortical surface in female rats.

In clinical studies, significant increases in BMD in the spine of osteopenic women were found at the end of the 1st, 2nd and 3rd years of treatment with 1,25(OH)2D3, while no positive effects in cholecalciferol treated women were observed (Zofkova and Hill 2007). Thus, it can be said that D-hormone metabolites have unambiguously positive effects on bone mass and microstructure.

**Conclusion**

Although a relatively good spectrum of molecules with osteogenic potential is available at the present time, their effects (positive or even detrimental) on the skeleton may differ in individual subjects depending on their genetic predisposition. New strategies in the therapy of osteolytic diseases using drugs with satisfactory beneficial potential for the skeleton and absent or minimal side effects are necessary. Identification of candidate genes (e.g. LRP5, PSL3 and WNT1) associated with the response of bone mass and bone quality to individual pharmaceuticals will make it possible to personalize curative strategies (reviewed by Rocha-Braz and Ferraz-de-Souza 2016, Zofkova et al. 2015).

**Conflict of Interest**

There is no conflict of interest.

**Acknowledgements**

This work was supported by the project (Ministry of Health, Czech Republic), for conceptual development of research organization 00023761 (Institute of Endocrinology, Prague, Czech Republic) and by the MEYS CR (OP RDE, Excellent research – ENDO.CZ).

**References**


LEDER BZ, TSAI JN, NEER RM, UIHLEIN AV, WALLACE PM, BURNETT-BOWIE SA: Response to therapy with teriparatide, denosumab, or both in postmenopausal women in the DATA (denosumab and teriparatide administration) Study Randomized Controlled Trial. *J Clin Densitom* **19**: 346-351, 2016.


